OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their ...

Oxford, UK-based biotech OMass Therapeutics today announced it has entered into an exclusive collaboration and license ...

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in ...

The OMass partnership will boost Roche’s strategy in inflammatory bowel diseases, currently led by afimkibart, an anti-TL1A ...

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program. | Roche’s Genentech unit has handed over ...

Eli Lilly and Novo Nordisk already produce popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site ...

Biotechnology pioneer Genentech broke ground Monday on a $700 million manufacturing facility in Holly Springs, marking the ...

San Francisco-based Genentech plans to create up to 420 high-paying jobs in Holly Springs — a project expected to bring an ...

Totality of data presented underscores the strength of Genentech’s broad, industry-leading development program, which aims to address the diverse needs, preferences and experiences of people ...

OMass inks exclusive collaboration and license agreement with Genentech to develop and commercialize therapies for inflammatory bowel disease: Oxford, UK Wednesday, September 3, 2 ...